Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Apr;97(4):808-15.
doi: 10.3945/ajcn.112.050021. Epub 2013 Feb 20.

DHA supplementation and pregnancy outcomes

Susan E Carlson  1 , John Colombo, Byron J Gajewski, Kathleen M Gustafson, David Mundy, John Yeast, Michael K Georgieff, Lisa A Markley, Elizabeth H Kerling, D Jill Shaddy
Affiliations
Clinical Trial

DHA supplementation and pregnancy outcomes

Susan E Carlson et al. Am J Clin Nutr. 2013 Apr.

Abstract

Background: Observational studies associate higher intakes of n-3 (omega-3) long-chain polyunsaturated fatty acids (LCPUFAs) during pregnancy with higher gestation duration and birth size. The results of randomized supplementation trials using various n-3 LCPUFA sources and amounts are mixed.

Objective: We tested the hypothesis that 600 mg/d of the n-3 LCPUFA docosahexaenoic acid (DHA) can increase maternal and newborn DHA status, gestation duration, birth weight, and length. Safety was assessed.

Design: This phase III, double-blind, randomized controlled trial was conducted between January 2006 and October 2011. Women (n = 350) consumed capsules (placebo, DHA) from <20 wk of gestation to birth. Blood (enrollment, birth, and cord) was analyzed for red blood cell (RBC) phospholipid DHA. The statistical analysis was intent-to-treat.

Results: Most of the capsules were consumed (76% placebo; 78% DHA); the mean DHA intake for the treated group was 469 mg/d. In comparison with placebo, DHA supplementation resulted in higher maternal and cord RBC-phospholipid-DHA (2.6%; P < 0.001), longer gestation duration (2.9 d; P = 0.041), and greater birth weight (172 g; P = 0.004), length (0.7 cm; P = 0.022), and head circumference (0.5 cm; P = 0.012). In addition, the DHA group had fewer infants born at <34 wk of gestation (P = 0.025) and shorter hospital stays for infants born preterm (40.8 compared with 8.9 d; P = 0.026) than did the placebo group. No safety concerns were identified.

Conclusions: A supplement of 600 mg DHA/d in the last half of gestation resulted in overall greater gestation duration and infant size. A reduction in early preterm and very-low birth weight could be important clinical and public health outcomes of DHA supplementation. This trial was registered at clinicaltrials.gov as NCT00266825.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Consolidated Standards of Reporting Trials flow diagram.
See this image and copyright information in PMC

References

    1. Olsen SF, Joensen HD. High liveborn birth weight in the Faroes: a comparison between birth weights in the Faroes and in Denmark. J Epidemiol Community Health 1985;39:27–32 - PMC - PubMed
    1. Campoy C, Escoano-Margarit V, Anjos T, Szajewska H, Uauy R. Omega 3 fatty acids on child growth, visual acuity and neurodevelopment. Br J Nutr 2012;107:S85–106 - PubMed
    1. Larqué E, Gil-Sanchez A, Prieto-Sanchez MT, Koletzko B. Omega 3 fatty acids, gestation and pregnancy outcomes. Br J Nutr 2012;107:S77–84 - PubMed
    1. Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by preeclampsia or intrauterine growth restriction. Cochrane Database of Systematic Reviews 2006;3. - PubMed
    1. Ramakrishnan U, Stein AD, Parra-Cabrera S, Wang M, Imhoff-Kunsch B, Juarez-Marquez S, Rivera J, Martorell R. Effect of docosahexaenoic acid supplementation during pregnancy on gestational age and size at birth: randomized double-blind, placebo-controlled trial in Mexico. Food Nutr Bull 2010;31:S108–16 - PubMed

Publication types

MeSH terms

Associated data